Artiva Biotherapeutics, Inc. Revenue
Artiva Biotherapeutics, Inc. (ARTV) reported Revenue of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-03-10
- Artiva Biotherapeutics, Inc. revenues for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Artiva Biotherapeutics, Inc. revenues for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Artiva Biotherapeutics, Inc. revenues for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Artiva Biotherapeutics, Inc. revenues for the quarter ending 2024-03-31 was $251.00K.
- Artiva Biotherapeutics, Inc. revenues for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Artiva Biotherapeutics, Inc. revenues for fiscal 2024 was $251.00K, a 99.25% decline from fiscal 2023.
- Artiva Biotherapeutics, Inc. revenues for fiscal 2023 was $33.49M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-10 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $0.00 derived: sum of 3 quarters · filed 2026-03-10 | $251.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $251.00K 10-Q · filed 2025-11-12 | $2.60M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $251.00K 10-Q · filed 2025-08-06 | $2.60M derived: sum of 3 quarters · filed 2025-08-06 | $29.26M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $251.00K 10-Q · filed 2025-05-08 | $2.60M derived: sum of 2 quarters · filed 2025-05-08 | $29.26M derived: sum of 3 quarters · filed 2025-05-08 | $32.75M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $29.01M derived: sum of 2 quarters · filed 2025-03-24 | $32.50M derived: sum of 3 quarters · filed 2025-03-24 | $33.49M 10-K · filed 2025-03-24 |
| 2023-09-30 | $26.66M 10-Q · filed 2024-11-12 | $30.15M derived: sum of 2 quarters · filed 2024-11-12 | $31.14M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $3.50M 10-Q · filed 2024-08-29 | $4.49M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |